Edition:
United States

Cleveland Biolabs Inc (CBLI.OQ)

CBLI.OQ on NASDAQ Stock Exchange Capital Market

3.72USD
26 May 2017
Change (% chg)

$-0.09 (-2.36%)
Prev Close
$3.81
Open
$3.83
Day's High
$3.83
Day's Low
$3.65
Volume
14,608
Avg. Vol
169,120
52-wk High
$5.55
52-wk Low
$1.22

Latest Key Developments (Source: Significant Developments)

Cleveland Biolabs Qtrly loss per share $0.15
Monday, 15 May 2017 07:30am EDT 

May 15 (Reuters) - Cleveland Biolabs Inc :Cleveland Biolabs reports first quarter 2017 financial results and development progress.Q1 revenue $600,000 versus $800,000.Qtrly loss per share $0.15.  Full Article

Cleveland Biolabs announces commencement of in Vivo Biocomparability study
Monday, 17 Apr 2017 07:36am EDT 

April 17 (Reuters) - Cleveland Biolabs Inc :Cleveland Biolabs announces commencement of in Vivo biocomparability study.FDA provided CBLI with its consent for initiation of an in Vivo Biocomparability study of the formulations in non-human primates.Planned biocomparability study is funded in part by department of defense joint Warfighter Medical Research Program contract.FDA completed its review of a side-by-side analytical comparison of two formulations of entolimod.  Full Article

Cleveland Biolabs announces European Medicines Agency positive opinion regarding entolimod pediatric investigation plan
Monday, 17 Apr 2017 07:30am EDT 

April 17 (Reuters) - Cleveland Biolabs Inc :Cleveland Biolabs announces European Medicines Agency positive opinion regarding the entolimod pediatric investigation plan.Cleveland Biolabs - EMA accepted co's pediatric investigation plan paving way for submission of MAA for entolimod as medical radiation countermeasure.  Full Article

Cleveland Biolabs reports Q4 loss per share $0.11
Wednesday, 22 Feb 2017 04:15pm EST 

Cleveland Biolabs Inc : Cleveland Biolabs reports 2016 financial results and development progress . Q4 loss per share $0.11 . Q4 revenue $1.0 million versus $1.3 million .Cleveland Biolabs - as of Dec 31, cash, cash equivalents, short-term investments estimated to fund operations for at least one year beyond filing of form 10-k.  Full Article

Cleveland Biolabs quarterly loss per share $0.17
Monday, 15 Aug 2016 08:30am EDT 

Cleveland Biolabs Inc :Quarterly loss per share $0.17.  Full Article

Cleveland Biolabs posts a loss of $0.06 per share in Q1
Monday, 16 May 2016 07:30am EDT 

Cleveland Biolabs Inc : Cleveland Biolabs reports first quarter 2016 financial results and development progress . Q1 loss per share $0.06 .Q1 revenue $800,000 versus $600,000.  Full Article

Cleveland Biolabs and CFO Neil Lyons agreed on Lyon's termination of employment
Friday, 6 May 2016 05:55pm EDT 

Cleveland Biolabs Inc : Co, Neil Lyons, Co's CFO mutually agreed that Lyons would terminate his employment with company effective May 6, 2016 .Lyons to become a consultant; in his role as a consultant, Lyons will continue to serve as CFO of company.  Full Article

Department of Defense Awards Cleveland BioLabs $9.2 Million Contract for Advanced Development of Entolimod as Medical Radiation Countermeasure
Wednesday, 2 Sep 2015 11:49am EDT 

Cleveland BioLabs Inc:Department of Defense awards Cleveland Biolabs a $9.2 million contract for advanced development of entolimod as a medical radiation countermeasure.Dod contract will fund pivotal animal studies designed to support future submission of biologics license application for entolimod.Dod awarded co contract valued at up to $9.2 million to support further development of entolimod as a medical radiation countermeasure.Submitted application for pre-emergency use authorization to FDA in support of use of entolimod as medical radiation countermeasure.  Full Article

Cleveland BioLabs Inc announces new patents strengthening Entolimod portfolio
Tuesday, 18 Aug 2015 08:00am EDT 

Cleveland BioLabs Inc:Says allowance or issuance of several new patents for entolimod in U.S. and other countries, further bolstering its patent position.  Full Article

Cleveland BioLabs Inc announces date change for second quarter 2015 financial results
Friday, 31 Jul 2015 01:00pm EDT 

Cleveland BioLabs Inc:Says on August 12, 2015, it will report its financial results for the second quarter and six-month period ended June 30, 2015.  Full Article

More From Around the Web

BRIEF-Cleveland Biolabs Qtrly loss per share $0.15

* Cleveland Biolabs reports first quarter 2017 financial results and development progress